

## CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



WIPO | PCT



(10) International Publication Number  
**WO 2013/003114 A8**

(43) International Publication Date  
3 January 2013 (03.01.2013)

## (51) International Patent Classification:

*A61K 9/00* (2006.01) *A61K 31/203* (2006.01)  
*A61K 31/16* (2006.01) *A61K 31/557* (2006.01)  
*A61K 31/201* (2006.01) *A61P 27/02* (2006.01)  
*A61K 31/202* (2006.01) *A61P 27/04* (2006.01)

## (21) International Application Number:

PCT/US2012/043079

## (22) International Filing Date:

19 June 2012 (19.06.2012)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/503,158 30 June 2011 (30.06.2011) US  
13/495,052 13 June 2012 (13.06.2012) US

(71) Applicant (for all designated States except US): **JOHNSON & JOHNSON VISION CARE, INC.** [US/US];  
7500 Centurion Parkway, Jacksonville, FL 32256 (US).

## (72) Inventor; and

(75) Inventor/Applicant (for US only): **GALLOIS, Annabelle**  
[FR/US]; 1553 Azalea Terrace, Jacksonville, FL 32205 (US).

(74) Agents: **JOHNSON, Philip, S.** et al.; Johnson & Johnson,  
One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

## Published:

- with international search report (Art. 21(3))

## (48) Date of publication of this corrected version:

25 July 2013

## (15) Information about Correction:

see Notice of 25 July 2013

(54) Title: ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS

(57) Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.



WO 2013/003114 A8